SCHEMBL5149872

SCHEMBL5149872

CC(C)N1CCC(=NO)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 1.00
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
PKM P14618 1/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 1/20 0.33
HRH3 Q9Y5N1 4/20 0.33
KCNH2 Q12809 2/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
EGFR P00533 1/20 0.31
PTK2 Q05397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13946083 0.86 CHRNA7 (0.76) CHRNA7TSHRCASP1CYP2D6CYP1A2
SCHEMBL12300196 0.78 CHRNA7 (0.64) CHRNA7CYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL13946082 0.74 CHRNA7 (0.59) CHRNA7TSHRCASP1HRH3EGFR
SCHEMBL8108453 0.73 CYP2D6 (0.63) CHRNA7CYP2D6KDM4EALDH1A1GAA
SCHEMBL6943669 0.73 CYP2D6 (0.63) CHRNA7CYP2D6KDM4EALDH1A1GAA
SCHEMBL10268675 0.73 CHRNA7 (0.57) CHRNA7CYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL1114221 0.72
SCHEMBL19459064 0.72 CHRNA7 (0.56) CHRNA7CYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL18843843 0.70 CHRNA7 (0.54) CHRNA7CYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL19459142 0.69 CHRNA7 (0.52) CHRNA7CYP2D6KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202840-B2 Compounds for the treatment or alleviation of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2025-01-21 US disclosed
CN-112313230-B Novel compounds for the treatment, alleviation or prevention of conditions associated with Tau aggregate AC免疫有限公司 2024-03-15 CN disclosed
EP-3802528-B1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2022-07-06 EP disclosed
EP-3802528-B1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2022-07-06 EP disclosed
US-20210214371-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2021-07-15 US disclosed
US-20210214371-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2021-07-15 US disclosed
EP-3802528-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC Immune SA (CH) 2021-04-14 EP disclosed
CN-112313230-A Novel compounds for treating, alleviating or preventing conditions associated with Tau aggregates AC免疫有限公司 2021-02-02 CN disclosed
WO-2019233745-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2019-12-12 WO disclosed
WO-2019233745-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2019-12-12 WO disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090012071-A1 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-08 US disclosed
WO-2007071840-A2 COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF CEREP (FR) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202840-B2 Compounds for the treatment or alleviation of disorders associated with Tau aggregates MAPT, MAP1LC3A, TUBB3 CHRNA7 449/4885TSHR 4275/4885CASP1 3180/4885
US-20210214371-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B CHRNA7 377/4885TSHR 4332/4885CASP1 2848/4885
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 CHRNA7 4853/4885TSHR 1650/4885CASP1 984/4885
US-20090012071-A1 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS TOP1, TOP2B, TOP2A CHRNA7 2510/4885TSHR 4685/4885CASP1 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.